SM
PACB icon

SG3 Management’s Pacific Biosciences PACB Stock Holding History

SG3 Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-24,000
Closed -$218K – 702
2022
Q1 		$218K Sell
24,000
-16,000
-40% -$184K 0.01% 745
2021
Q4 		$818K Buy
+40,000
New +$965K 0.02% 531

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

SG3 Management's PACB Position: Q3 2021 in Review

SG3 Management sold out of Pacific Biosciences (PACB) in Q3 2021, closing a stake of 10,000 shares — an estimated $350K sold.

SG3 Management first reported a position in PACB in Q1 2021 and held it in 2 quarters. The position peaked at $350K in Q2 2021. 246 funds tracked by Wall St. Rank hold PACB as of Q3 2021.

  • SG3 Management reported no remaining Pacific Biosciences position as of Q3 2021 after selling out during the quarter.
  • SG3 Management sold 10,000 Pacific Biosciences shares in Q3 2021, an estimated $350K.
  • SG3 Management first reported a position in Pacific Biosciences in Q1 2021 and held it in 2 quarters.
  • SG3 Management's Pacific Biosciences position peaked at $350K in Q2 2021.
  • 246 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2021.

Based on SG3 Management's 13F filing for Q3 2021, filed 15 Nov 2021.